

# KPQC Learning Forum

---

August 2025



# SHTN Bundle Update

---

## Protocols

\*Who needs to send?



\*Who has not?

**POSTBIRTH** includes Birth Equity training, other options as needed

\*POSTBIRTH seats coming available, information from Kari soon!

\*POSTBIRTH magnets- coming soon!

**Data!** Update from Michelle



# *Severe Hypertension in Pregnancy*

Model for Kansas

# Rapid Response

---

Advances in Preeclampsia Diagnostics



## Is Prediction of Preeclampsia Achievable? The Stars May Be Aligning

Christine Kilgore  
August 01, 2025

1 45

[Add to Email Alerts](#)

Clinicians and researchers have long dreamed of accurate screening tools for preeclampsia — tools that could lead to detection before symptoms manifest and then targeted treatment.

The medical literature is replete with reports of preeclampsia predictors that were accurate but subsequently failed to take hold in clinical practice in the US. After years of rising incidence, preeclampsia now affects 1 in 12 pregnancies.

Some of these reports described studies that were small or not externally validated. Others described combinations of clinical factors and biochemical tests that were endorsed by professional bodies overseas but weren't tested here or weren't deemed practical enough for clinical practice in the US.

**Which Breast Cancer Subtype Is Most Associated With Bone Metastasis?**  
Answer this and 4 other questions in our Fast Five Quiz. [Test Your Knowledge](#)

Now, there are signs of real progress — from growing attention to analytes such as placental growth factor (PIGF) to new studies of maternal circulating cell-free RNA (cfRNA) and cfDNA and new therapeutic studies.

## Is Prediction of Preeclampsia Achievable? The Stars May Be Aligning - Medscape - August 01, 2025.

### Molecular Subtyping and Preeclampsia Prediction With RNA Testing

The goal is to use biologic predictors rather than weakly predictive, sometimes ambiguous clinical and demographic characteristics to predict preeclampsia.

On one front, recent studies have shown promising predictive power with placental-derived cfRNA and cfDNA. In a [large study](#) sponsored by Mirvie (San Francisco), researchers analyzed transcriptomic data from blood collected at 17.5-22 weeks in a prospective cohort of over 9000 pregnant individuals who were 35 years or older and had no other preexisting high-risk conditions.

They identified distinct plasma cfRNA profiles capable of predicting preeclampsia — one reflecting the activation of placental genes like *PAPPA2* that are associated with placental dysfunction, and the other correlating with “genes associated with maternal immune activity, probably inflammation, and probably some aspect of cardiovascular adaptation and systemic response,” said co-investigator Thomas F. McElrath, MD, PhD, professor of obstetrics, gynecology and reproductive biology at Harvard Medical School, Boston, and vice president for Clinical Development at Mirvie.



Thomas F.  
McElrath, MD,  
PhD

The two signatures align, respectively, with what researchers and clinicians have increasingly regarded as two distinct phenotypes of preeclampsia: an earlier form typically occurring before 34-35 weeks gestation and leading to preterm delivery or severe features, and a later form occurring at term.



<https://www.medscape.com/viewarticle/prediction-preeclampsia-achievable-stars-may-be-aligning-2025a1000kir>


# Rapid Response

---


Maternal Mental Health, Substance Abuse Disorder, Intimate Partner Violence



# SHTN Model for Kansas



# Community Support for Positive Clinical Outcomes



# *IPV, SUD, Perinatal Mood Disorder*

*October 14<sup>th</sup> &  
October 21<sup>st</sup>*

## *GOALS for SHTN facilities: (Birthing and Non-birthing)*

- PATIENT is the focus, not the checklist
- Making connections for patients with intimate partner violence
- Debrief and mental health referral post-discharge for births with trauma
- Bedside, phone triage, etc ALL partners are in

# CUES Training (Intimate Partner Violence)

1	Center	Received CUES Training in 2024/2025	Has Received TA
2	Advent Health Shawnee Mission	Y	Y
3	AdventHealth South Overland Park	Y	Y
4	Amberwell Hiawatha		
5	Ascension Via Christi Manhattan	Y	
6	Atchison Hospital Association dba Amberwell Atchison		
7	Citizens Medical Center		
8	Clay County Medical Center	Y	Y
9	Coffey County Hospital		
10	Coffeyville Regional Medical Center		
11	Community Healthcare System		
12	Gove Regional Medical Center		
13	Hays Medical Center ("HaysMed")	Y	Y
14	Hutchinson Regional Medical Center		
15	Kearny County Hospital	Y	
16	Labette Health		
17	Lawrence Memorial Hospital		
18	McPherson County	Y	Y
19	Mitchell County Hospital Health System		
20	Nemaha Valley Community Hospital	Y	Y
21	Neosho Memorial Regional Medical Center	Y	Y
22	Newman Regional Health	Y	
23	NMC (Newton)		
24	Overland Park Regional		
25	Pratt Regional Medical Center		
26	Republic County Hospital		
27	Hospital District #1 of Rice County		
28	Sabetha Community Hospital		
29	Salina Regional Health Center		Y
30	Southwest Medical Center	Y	Y
31	Stormont Vail Health	Y	Y
32	Stormont Vail Health Flinthills	Y	
33	Susan B Allen Memorial Hospital		
34	University of Kansas Health System- Great Bend	Y	
35	University of Kansas Health System-KC		
36	University of Kansas Health System- Olathe	Y	Y
37	University of Kansas Health System- St. Francis		
38	Wesley Medical Center	Y	Y
39	William Newton Hospital		
40			



# BRIDGES TO WELLNESS

## CONNECTING MENTAL HEALTH, SUBSTANCE USE & INTIMATE PARTNER VIOLENCE IN PERINATAL CARE

A free, two-part webinar training series for KPQC-enrolled hospitals. All staff and providers are encouraged to attend. The sessions will address perinatal mood disorders, substance use disorder, and intimate partner violence, with practical tools for implementation and follow-up technical assistance as needed.



**SESSION 1**  
**Maternal Mental Health and Substance Use Disorder in the Inpatient Setting**  
 Kansas Connecting Communities (KCC) Team  
**Date: October 14, 2025**  
**Time: 12:00 – 1:00 PM**

**SESSION 2**  
**Intimate Partner Violence in the Perinatal Setting: CUES Training**  
 MAVIS Team  
**Date: October 21, 2025**  
**Time: 12:00 – 1:00 PM**



# Rapid Response

---

AAP Vaccine Update: 2025



# AAP Vaccine update: 2025

[AAP-Immunization-Schedule.pdf](#)

**Table 1** Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2025

American Academy of Pediatrics  
DEDICATED TO THE HEALTH OF ALL CHILDREN®

These recommendations must be read with the Notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the outlined purple bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

Vaccine and other immunizing agents	Birth	1 mos	2 mos	4 mos	6 mos	8 mos	9 mos	12 mos	15 mos	18 mos	19–23 mos	2–3 yrs	4–6 yrs	7–10 yrs	11–12 yrs	13–15 yrs	16 yrs	17–18 yrs			
Respiratory syncytial virus (RSV-mAb [nirsevimab, clesrovimab])	1 dose during RSV season depending on maternal RSV vaccination status (See Notes)		1 dose during RSV season (See Notes)																		
Hepatitis B (HepB)	1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose																		
Rotavirus (RV): RV1 (2-dose series), RVS (3-dose series)	1 <sup>st</sup> dose		2 <sup>nd</sup> dose	See Notes																	
Diphtheria, tetanus, and acellular pertussis (DTaP <7 yrs)	1 <sup>st</sup> dose		2 <sup>nd</sup> dose	3 <sup>rd</sup> dose	4 <sup>th</sup> dose										5 <sup>th</sup> dose						
Haemophilus influenzae type b (Hib)	1 <sup>st</sup> dose		2 <sup>nd</sup> dose	See Notes		3 <sup>rd</sup> or 4 <sup>th</sup> dose (See Notes)										4 <sup>th</sup> dose					
Pneumococcal conjugate (PCV15, PCV20)	1 <sup>st</sup> dose		2 <sup>nd</sup> dose	3 <sup>rd</sup> dose	4 <sup>th</sup> dose																
Inactivated poliovirus (IPV)	1 <sup>st</sup> dose		2 <sup>nd</sup> dose	3 <sup>rd</sup> dose										4 <sup>th</sup> dose							
COVID-19 (1vCOV-mRNA, 1vCOV-aPS)	1 or more doses of 2025–2026 vaccine (See Notes)																				
Influenza	1 or 2 doses annually (See Notes)																				
Measles, mumps, and rubella (MMR)	See Notes																				
Varicella (VAR)	1 <sup>st</sup> dose																				
Hepatitis A (HepA)	See Notes																				
Tetanus, diphtheria, and acellular pertussis (Tdap ≥7 yrs)	1 <sup>st</sup> dose																				
Human papillomavirus (HPV)	2-dose series																				
Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2 years)	See Notes																				
Meningococcal B (MenB-4C, MenB-FHbp)	See Notes																				
Respiratory syncytial virus vaccine (RSV [Abrysvo])	Seasonal administration (See Notes)																				
Dengue (DEN4CYD: 9–16 yrs)	Seropositive in endemic dengue (See Notes)																				
Mpox	See Notes																				

● Range of recommended ages for all children
 ● Range of recommended ages for catch-up vaccination
 ● Range of recommended ages for certain high-risk groups or populations
 ● Recommended vaccination for those who desire protection
 ● Recommended vaccine on shared clinical decision

**Table 3** Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2025

American Academy of Pediatrics  
DEDICATED TO THE HEALTH OF ALL CHILDREN®

Always use this table in conjunction with Table 1 and the Notes that follow. Medical conditions are often not mutually exclusive. If multiple conditions are present, refer to guidance in all relevant columns. See Notes for medical conditions not listed.

Vaccine and other immunizing agents	Pregnancy	Immunocompromised (excluding HIV infection) <sup>a</sup>	HIV infection CD4 percentage and count <sup>a</sup> <15%/mm <sup>3</sup> or <200/mm <sup>3</sup>	HIV infection CD4 percentage and count <sup>a</sup> ≥15% and ≥200/mm <sup>3</sup>	CSF leak or cochlear implant	Asplenia or persistent complement component deficiencies	Heart disease or chronic lung disease	Kidney failure, End-stage renal disease or on dialysis	Chronic liver disease	Diabetes	
RSV-mAb (nirsevimab, clesrovimab)		2 <sup>nd</sup> RSV season	1 dose depending on maternal RSV vaccination status (See Notes)				2 <sup>nd</sup> RSV season for chronic lung disease (See Notes)	1 dose depending on maternal RSV vaccination status (See Notes)			
Hepatitis B		See Notes									
Rotavirus		SCID <sup>b</sup>		See Notes							
DTaP/Tdap	DTaP: not applicable Tdap: 1 dose each pregnancy	See Notes									
Hib		HCT <sup>c</sup> : 3 doses	See Notes		See Notes						
Pneumococcal		See Notes									
IPV		See Notes									
COVID-19	*	See Notes									
Influenza inactivated, recombinant		Solid organ transplant: 18 yrs (See Notes)		See Notes							
LAIV3		See Notes						Asthma, wheezing: 2–4 years <sup>d</sup>	See Notes		
MMR	**	See Notes									
VAR	**	See Notes									
Hepatitis A		See Notes									
HPV	**	3-dose series (See Notes)		See Notes							
MenACWY		See Notes									
MenB		See Notes									
RSV (Abrysvo)	Seasonal administration (See Notes)	See Notes									
Dengue		See Notes									
Mpox	See Notes	See Notes									

\*Referring to the Immunization Schedule endorsed by AAP in November 2024; will update as needed when the American College of Obstetricians and Gynecologists releases 2025–2026 guidance.

● Recommended for all age-eligible children who lack documentation of a complete vaccination series
 ● Not recommended for all children, but recommended for some children based on increased risk for or severe outcomes from disease
 ● Recommended for all age-eligible children, but recommended for some children based on medical condition or other indications. See Notes.
 ● Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction
 ● Contraindicated or not recommended. \*\*Vaccinate after pregnancy, if indicated

a. For additional information regarding immunization in immunocompromised children, see <https://publications.aap.org/redbook/book/755/chapter/74074446/Immunization-and-Other-Considerations-in-Immunocompromised-Children>  
 b. Severe combined immunodeficiency  
 c. Hematopoietic cell transplantation  
 d. LAIV3 contraindicated for children 2–4 years of age with asthma or wheezing during the preceding 12 months



# Rapid Response: Updated sterilization consent

[https://portal.kmap-state-ks.us/Documents/Provider/Bulletins/25190%20-%20Updated Sterilization Consent For ms.pdf](https://portal.kmap-state-ks.us/Documents/Provider/Bulletins/25190%20-%20Updated%20Sterilization%20Consent%20For%20ms.pdf)

Form Approved: OMB No. 0937-0166  
Expiration date: 7/31/2028

## CONSENT FOR STERILIZATION

**NOTICE:** YOUR DECISION AT ANY TIME NOT TO BE STERILIZED WILL NOT RESULT IN THE WITHDRAWAL OR WITHHOLDING OF ANY BENEFITS PROVIDED BY PROGRAMS OR PROJECTS RECEIVING FEDERAL FUNDS.

### ■ CONSENT TO STERILIZATION ■

I have asked for and received information about sterilization from \_\_\_\_\_, When I first asked \_\_\_\_\_, \_\_\_\_\_  
*Doctor or Clinic*

for the information, I was told that the decision to be sterilized is completely up to me. I was told that I could decide not to be sterilized. If I decide not to be sterilized, my decision will not affect my right to future care or treatment. I will not lose any help or benefits from programs receiving Federal funds, such as Temporary Assistance for Needy Families (TANF) or Medicaid that I am now getting or for which I may become eligible.

I UNDERSTAND THAT THE STERILIZATION MUST BE CONSIDERED PERMANENT AND NOT REVERSIBLE. I HAVE DECIDED THAT I DO NOT WANT TO BECOME PREGNANT, BEAR CHILDREN OR FATHER CHILDREN.

I was told about those temporary methods of birth control that are available and could be provided to me which will allow me to bear or father a child in the future. I have rejected these alternatives and chosen to be sterilized.

I understand that I will be sterilized by an operation known as a \_\_\_\_\_, \_\_\_\_\_  
*Specify Type of Operation*

and benefits associated with the operation have been explained to me. All my questions have been answered to my satisfaction.

I understand that the operation will not be done until at least 30 days after I sign this form. I understand that I can change my mind at any time and that my decision at any time not to be sterilized will not result in the withholding of any benefits or medical services provided by federally funded programs.

I am at least 21 years of age and was born on: \_\_\_\_\_  
*Date*

I, \_\_\_\_\_, hereby consent of my own free will to be sterilized by \_\_\_\_\_  
*Doctor or Clinic*

by a method called \_\_\_\_\_, My \_\_\_\_\_  
*Specify Type of Operation*

consent expires 180 days from the date of my signature below.

I also consent to the release of this form and other medical records about the operation to:

Representatives of the Department of Health and Human Services, or Employees of programs or projects funded by the Department but only for determining if Federal laws were observed.

I have received a copy of this form.

\_\_\_\_\_  
*Signature* \_\_\_\_\_  
*Date*

You are requested to supply the following information, but it is not required. (*Ethnicity and Race Designation*) (please check)

- Ethnicity:*
- Hispanic or Latino  American Indian or Alaska Native  
 Not Hispanic or Latino  Asian  
 Black or African American  
 Native Hawaiian or Other Pacific Islander  
 White

### ■ INTERPRETER'S STATEMENT ■

If an interpreter is provided to assist the individual to be sterilized:

I have translated the information and advice presented orally to the individual to be sterilized by the person obtaining this consent. I have also read him/her the consent form in \_\_\_\_\_

language and explained its contents to him/her. To the best of my knowledge and belief he/she understood this explanation.

\_\_\_\_\_  
*Interpreter's Signature* \_\_\_\_\_  
*Date*

### ■ STATEMENT OF PERSON OBTAINING CONSENT ■

Before \_\_\_\_\_ signed the

\_\_\_\_\_  
*Name of Individual*

consent form, I explained to him/her the nature of sterilization operation

\_\_\_\_\_, the fact that it is \_\_\_\_\_  
*Specify Type of Operation*

intended to be a final and irreversible procedure and the discomforts, risks and benefits associated with it.

I counseled the individual to be sterilized that alternative methods of birth control are available which are temporary. I explained that sterilization is different because it is permanent. I informed the individual to be sterilized that his/her consent can be withdrawn at any time and that he/she will not lose any health services or any benefits provided by Federal funds.

To the best of my knowledge and belief the individual to be sterilized is at least 21 years old and appears mentally competent. He/She knowingly and voluntarily requested to be sterilized and appears to understand the nature and consequences of the procedure.

\_\_\_\_\_  
*Signature of Person Obtaining Consent* \_\_\_\_\_  
*Date*

\_\_\_\_\_  
*Facility*

\_\_\_\_\_  
*Address*

### ■ PHYSICIAN'S STATEMENT ■

Shortly before I performed a sterilization operation upon \_\_\_\_\_

\_\_\_\_\_ on \_\_\_\_\_  
*Name of Individual* \_\_\_\_\_  
*Date of Sterilization*

I explained to him/her the nature of the sterilization operation

\_\_\_\_\_, the fact that it is \_\_\_\_\_  
*Specify Type of Operation*

intended to be a final and irreversible procedure and the discomforts, risks and benefits associated with it.

I counseled the individual to be sterilized that alternative methods of birth control are available which are temporary. I explained that sterilization is different because it is permanent.

I informed the individual to be sterilized that his/her consent can be withdrawn at any time and that he/she will not lose any health services or benefits provided by Federal funds.

To the best of my knowledge and belief the individual to be sterilized is at least 21 years old and appears mentally competent. He/She knowingly and voluntarily requested to be sterilized and appeared to understand the nature and consequences of the procedure.

(Instructions for use of alternative final paragraph: Use the first paragraph below except in the case of premature delivery or emergency abdominal surgery where the sterilization is performed less than 30 days after the date of the individual's signature on the consent form. In those cases, the second paragraph below must be used. Cross out the paragraph which is not used.)

(1) At least 30 days have passed between the date of the individual's signature on this consent form and the date the sterilization was performed.

(2) This sterilization was performed less than 30 days but more than 72 hours after the date of the individual's signature on this consent form because of the following circumstances (check applicable box and fill in information requested):

- Premature delivery  
 Individual's expected date of delivery: \_\_\_\_\_  
 Emergency abdominal surgery (describe circumstances): \_\_\_\_\_

\_\_\_\_\_  
*Physician's Signature* \_\_\_\_\_  
*Date*



# KPQC: What's on the "MENU"?

## KPQC options for Shared Resources & Education Survey update

- Those that have completed the survey:**
- Amberwell Hiawatha
  - Cheyenne County Hospital
  - Citizens Health
  - Coffeyville Med Center
  - FW Huston Med Center
  - HaysMed
  - Hamilton County Hospital
  - Labette Health
  - Kearny County Hospital
  - McPherson County Hospital
  - NMC Health
  - Newman Regional Health
  - Stormont Vail Health Topeka
  - Stormont Flinthills Campus
  - UKHS Olathe
  - Wesley Medical Center

1	SHTN Birthing & Non-birthing Facilities	
2	Resource Menu	6.25
3		
4	<b>Project</b>	<b>Project Lead</b>
5	Maternal Warning Signs	Kansas Perinatal Quality Collaborative (KPQC)
6	Hypertensive Disease in Pregnancy & Postpartum	KPQC
7	Maternal Mental Health	Kansas Connecting Communities (KCC)
8	Intimate Partner Violence	Maternal Anti-Violence Innovation and Sharing (MAVIS) & KCC
9	Breastfeeding: training & education	Kansas Breastfeeding Coalition
10	Breastfeeding: Hospital Designation A	High 5 for Mom & Baby, KS
11	Breastfeeding: Hospital Designation B	Baby Friendly, KS
12	Birth Equity	KS Birth Equity Network
13	Fetal monitoring	Fetal monitoring
14	SDDOH needs: Inpatient to Outpatient referral options (local)	Kansas Perinatal Community Collaborative
15	OB Navigation, Community Health Workers, Doula, Home Visiting options (local)	Kansas Dept of Health & Environment: Maternal Child Health
16	OB Simulations	KPQC
17	OB Emergency Readiness Kit	KPQC
18	Family Planning	KPQC
19	EMS Transfers (local)	KPQC
20	Neonatal Abstinence Syndrome	KPQC
21		
22		



# Rapid Response: Articles r/t AIM Bundle \*\*PROVIDERS\*\*

<b>Severe Hypertension (HTN) AIM-enrolled facilities</b>	<i>Education resource list for Staff &amp; Providers 2025</i>
	Kansas Perinatal Quality Collaborative: <i>Staff &amp; Project Leads</i> Terrah Stroda, CNM    tstroda@gmail.com      Kari Smith, RNC    kari.smith@kansaspqc.org
<b>PROJECT</b>	<b>Resources</b>
Kansas AIM Safety Bundle: Severe HTN in PG	<a href="#">Severe Hypertension In Pregnancy   AIM</a>
Hypertensive Disorders in Pregnancy	<a href="#">Severe Hypertension in Pregnancy Initiative Facts Sheet</a> <a href="#">Severe Hypertension   ACOG</a> *Includes algorithms & protocols for all Hypertensive Diseases of Pregnancy <a href="#">ACOG Chronic Hypertension In Pregnancy Article</a> <a href="#">The assessment of blood pressure in pregnant women: pitfalls and novel approaches - PubMed</a> <a href="#">Educating Patients Preeclampsia Foundation resource</a>
POSTBIRTH: Maternal Warning Signs	<a href="#">Maternal-Warning-Signs-Patient-Education-Toolkit-Binder5-final.pdf</a> *Training & Resources: Contact Kari Smith, KPQC
Birth Equity	<a href="#">HEAR HER Campaign   HEAR HER Campaign   CDC</a> <a href="#">Kansas Birth Equity Network</a> <a href="#">Patient Debriefs after Adverse Outcome &amp; Birth Equity Training</a>
Intimate Partner Violence	For training, Contact: Terrah Stroda, KPQC <a href="#">Intimate Partner Violence   ACOG</a>
Maternal Mental Health (Provider Consult Line, training, resources)	<a href="#">Maternal Mental Health</a> . Training, Contact Terrah Stroda, KPQC
AWHONN Fetal Monitoring Course	For training contact: Kari Smith, KPQC
Home Blood Pressure Monitoring: The Cuff Project	<a href="#">About The Cuff Kit®</a>
OB Simulations	Training statewide, Contact: Kari Smith, KPQC
<b>Other important HTN-related articles</b>	
ACOG: SHTN and long term implications	<a href="#">Long-Term Cardiovascular Risk in Women With Hypertension During Pregnancy - PubMed</a>
ACOG: Low dose Aspirin in Pregnancy	<a href="#">Low-Dose Aspirin Use During Pregnancy   ACOG</a>
PP visit schedule	<a href="#">ACOG Committee Opinion 736 Optimizing Postpartum Care</a> <a href="#">ACOG Consensus Bundle on Postpartum Care Basics</a>
Primary Csection prevention	<a href="#">Quality-Improvement Strategies for Safe Reduction of Primary Cesarean Birth   ACOG</a>
HTN in PG protocols	<a href="#">Severe Hypertension   ACOG</a>
OB Emergency Treatment: Severe HTN	<a href="#">ACOG Committee Opinion No. 767: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period - PubMed</a> <a href="#">Female age 15-50 years present to ED Triage</a>
Trauma Informed Care	<a href="#">Integrating Trauma-Informed Care Into Maternity Care Practice: Conceptual and Practical Issues - Sperlich - 2017 - Journal of Midwifery &amp; Women's Health - Wiley Online Library</a>
AMA: Implicit Bias	<a href="#">New AMA policies recognize race as a social, not biological, construct   Social construction of race   AMA</a>
KDHE: Annual Reports 2023 (include state births, morbidity, mortality)	<a href="#">KDHE 2023 Prenatal Care Report</a> <a href="#">KDHE 2023 Annual Summary of Vital Statistics</a>
Medscape: Preeclampsia Prediction	<a href="#">Preeclampsia Prediction Moving Closer to Reality</a>



# Kansas Cuff Project

**Kansas Cuff Project** works with local hospitals and clinics to:

- Initiate home blood pressure monitoring for patients for improved identification of HTN, which relates to faster treatment in pregnancy and postpartum
- Collaborate with outpatient and inpatient resources for education and treatment for HTN disease in pregnancy and postpartum care
- Educate statewide on maternal warning signs, including s/s of worsening hypertensive disease

# Finally, close to a LAUNCH!!!

---

## **Kansas Cuff Project, a three- tiered plan to:**

1- **Educate statewide on POSTBIRTH** maternal warning signs

With identification and rapid response to treatment when the patient presents to the outpatient/inpatient setting

2- **Launch a pilot project in eight high-risk Kansas counties** that will provide free BP cuffs to provider-identified patients

This will mirror the national Preeclampsia Foundation's Cuff Project and is a collaborative model with KDHE to connect outpatient and inpatient agencies in the identification and rapid treatment of hypertension in pregnant and postpartum patients.

3- **Launch statewide help for providers to order BP cuffs** covered through various payors, working to eliminate barriers to rapid distribution.

# Featured Speaker

---

Denise Fryzelka, CNM, FACNM, and lottttts more letterssss





## *Denise Fryzelka, CNM, PhD, APNP, FACNM*

Denise has over 25 years of experience providing midwifery care, education, and advocating for individuals and partnerships across many models of care. She has practiced in diverse roles and settings, including birth centers and hospitals such as Haiti, Guatemala, Europe, and the United States.

Currently Dr. Fryzelka works in a high volume academic clinical hospital-based midwifery practice at UW Hospitals and Clinics in Madison Wisconsin. She also brings a unique blend of practice and evidence-based consulting, strategies and coaching as a Coach and Consultant with Grow Midwives LLC.

Denise also centralizes diversity, equity and inclusion by providing not only tools for caring diverse populations, but also equity-minded frameworks and action-based results. Her doctoral research focused on Healthcare Provider Influence on Health Behavioral Modification in Gestational Diabetics and prevention of Diabetes.

# Next Learning Forum 9/23/25

Please contact us with any questions at Terrah Stroda [tstroda@gmail.com](mailto:tstroda@gmail.com) or Kari Smith [kari.smith@kansaspqc.org](mailto:kari.smith@kansaspqc.org)

